{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706777",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706777_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">Aceclofenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aceclofenac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706778",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706778_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the effects of   acenocoumarol .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706779",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706779_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-drug\">Aluminium hydroxide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aluminium hydroxide   is predicted to   decrease   the absorption of   deflazacort .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aluminium hydroxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706780",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706780_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   amifampridine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706781",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706781_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">aminophylline</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  aminophylline  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706782",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706782_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   amiodarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706783",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706783_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   amisulpride .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706784",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706784_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">amphotericin</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  amphotericin  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706785",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706785_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   anagrelide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706786",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706786_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   apalutamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706787",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706787_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   apomorphine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706788",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706788_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   arsenic trioxide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706789",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706789_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   artemether .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706790",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706790_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   artenimol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706791",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706791_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the concentration of   aspirin   (high-dose)  and  aspirin   (high-dose)   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706792",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706792_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706793",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706793_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"atezolizumab\" outputclass=\"int-drug\">atezolizumab</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the efficacy of   atezolizumab .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atezolizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706794",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706794_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"atracurium\" outputclass=\"int-drug\">atracurium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   atracurium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atracurium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706795",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706795_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-Guérin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-Guérin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-Guérin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-Guérin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706796",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706796_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">bambuterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  bambuterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706797",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706797_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   bedaquiline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706798",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706798_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  bendroflumethiazide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706799",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706799_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">Benzydamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Benzydamine   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706800",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706800_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   bosutinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706801",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706801_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">Bromfenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bromfenac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706802",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706802_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  bumetanide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706803",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706803_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   cabozantinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706804",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706804_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706805",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706805_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706806",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706806_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   ceritinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706807",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706807_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  chlorothiazide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706808",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706808_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   chlorpromazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706809",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706809_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  chlortalidone  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706810",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706810_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"choline salicylate\" outputclass=\"int-drug\">choline salicylate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the concentration of   choline salicylate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Choline salicylate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"cisatracurium\" outputclass=\"int-drug\">cisatracurium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   cisatracurium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisatracurium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   citalopram .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706813_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clarithromycin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   crizotinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706817",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706817_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706818",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706818_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dasatinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706819",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706819_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the risk of gastrointestinal bleeding when given with   deferasirox .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706820",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706820_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   delamanid .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706821",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706821_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexibuprofen\" outputclass=\"int-drug\">Dexibuprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexibuprofen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706822",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706822_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">Dexketoprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexketoprofen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706823",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706823_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">Diclofenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diclofenac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706824",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706824_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of digoxin toxicity when given with</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the risk of digoxin toxicity when given with   digoxin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706825",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706825_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dinutuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706826",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706826_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   disopyramide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706827",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706827_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706828",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706828_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   droperidol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706829",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706829_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   efavirenz .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706830",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706830_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   encorafenib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706831",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706831_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706832",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706832_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   eribulin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706833",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706833_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   increases   the risk of gastrointestinal perforation when given with   erlotinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706834",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706834_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   erythromycin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706835",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706835_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   escitalopram .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706836",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706836_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706837",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706837_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">Etoricoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etoricoxib   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706838",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706838_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"felbinac\" outputclass=\"int-drug\">Felbinac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Felbinac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felbinac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706839",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706839_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   flecainide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706840",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706840_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   fluconazole .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706841",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706841_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   fluphenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluphenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706842",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706842_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">Flurbiprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Flurbiprofen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706843",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706843_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"formoterol\" outputclass=\"int-drug\">formoterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  formoterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706844",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706844_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706845",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706845_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706846",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706846_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  furosemide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706847",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706847_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">opposes</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"glycerol phenylbutyrate\" outputclass=\"int-drug\">glycerol phenylbutyrate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor ammonia concentrations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   potentially   opposes   the effects of   glycerol phenylbutyrate .  Manufacturer advises monitor ammonia concentrations .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glycerol phenylbutyrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706848",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706848_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   haloperidol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706849",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706849_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  hydrochlorothiazide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706850",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706850_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  hydroflumethiazide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706851",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706851_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   hydroxyzine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706852",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706852_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">Ibuprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ibuprofen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706853",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706853_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706854",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706854_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">indacaterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  indacaterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706855",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706855_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  indapamide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706856",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706856_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indometacin\" outputclass=\"int-drug\">Indometacin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indometacin   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706857",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706857_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706858",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706858_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   inotuzumab ozogamicin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706859",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706859_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"ipilimumab\" outputclass=\"int-drug\">ipilimumab</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the efficacy of   ipilimumab .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ipilimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706860",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706860_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706861",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706861_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706862",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706862_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">Ketoprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoprofen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706863",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706863_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">Ketorolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketorolac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706864",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706864_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lapatinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706865",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706865_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lenvatinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706866",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706866_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   levomepromazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706867",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706867_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706868",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706868_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lofexidine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706869",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706869_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706870",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706870_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"magnesium carbonate\" outputclass=\"int-drug\">Magnesium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Magnesium carbonate   is predicted to   decrease   the absorption of   deflazacort .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Magnesium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706871",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706871_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"magnesium trisilicate\" outputclass=\"int-drug\">Magnesium trisilicate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Magnesium trisilicate   is predicted to   decrease   the absorption of   deflazacort .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Magnesium trisilicate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706872",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706872_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706873",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706873_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">Mefenamic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefenamic acid   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706874",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706874_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706875",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706875_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   methadone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706876",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706876_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  metolazone  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706877",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706877_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the efficacy of   mifamurtide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mifepristone\" outputclass=\"int-drug\">Mifepristone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mifepristone   is predicted to   decrease   the efficacy of   deflazacort .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifepristone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"mivacurium\" outputclass=\"int-drug\">mivacurium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   mivacurium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mivacurium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   moxifloxacin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">Nabumetone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nabumetone   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"naproxen\" outputclass=\"int-drug\">Naproxen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Naproxen   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nepafenac\" outputclass=\"int-drug\">Nepafenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nepafenac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nepafenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">nicorandil</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   increases   the risk of gastrointestinal perforation when given with   nicorandil .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   nilotinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"nivolumab\" outputclass=\"int-drug\">nivolumab</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the efficacy of   nivolumab .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nivolumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">olodaterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  olodaterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706889",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706889_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   ondansetron .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706890",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706890_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   osimertinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706891",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706891_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   paliperidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706892",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706892_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"pancuronium\" outputclass=\"int-drug\">pancuronium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   pancuronium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pancuronium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706893",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706893_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   panobinostat .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706894",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706894_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">Parecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Parecoxib   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706895",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706895_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   pasireotide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706896",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706896_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   pazopanib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706897",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706897_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"pembrolizumab\" outputclass=\"int-drug\">pembrolizumab</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the efficacy of   pembrolizumab .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pembrolizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706898",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706898_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"phenindione\" outputclass=\"int-drug\">phenindione</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the effects of   phenindione .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706899",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706899_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706900",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706900_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706901",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706901_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   pimozide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706902",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706902_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">Piroxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Piroxicam   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706903",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706903_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706904",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706904_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   quinine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706905",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706905_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   ranolazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706906",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706906_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   ribociclib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706907",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706907_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   deflazacort .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706908",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706908_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   risperidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706909",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706909_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706910",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706910_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"rocuronium\" outputclass=\"int-drug\">rocuronium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   rocuronium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rocuronium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706911",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706911_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706912",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706912_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">salbutamol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  salbutamol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706913",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706913_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">salmeterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  salmeterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706914",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706914_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Saquinavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706914_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">saquinavir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   saquinavir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706915",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706915_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   sildenafil .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706916",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706916_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"sodium phenylbutyrate\" outputclass=\"int-drug\">sodium phenylbutyrate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   potentially   decreases   the effects of   sodium phenylbutyrate .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium phenylbutyrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706917",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706917_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"somatropin\" outputclass=\"int-drug\">somatropin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   somatropin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Somatropin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706918",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706918_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   sorafenib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706919",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706919_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   sotalol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706920",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706920_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sulindac\" outputclass=\"int-drug\">Sulindac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sulindac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706921",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706921_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   sulpiride .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706922",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706922_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   sunitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706923",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706923_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"suxamethonium\" outputclass=\"int-drug\">suxamethonium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   decrease   the effects of   suxamethonium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Suxamethonium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706924",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706924_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   telavancin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706925",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706925_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">Tenoxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenoxicam   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706926",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706926_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">terbutaline</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  terbutaline  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706927",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706927_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706928",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706928_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"theophylline\" outputclass=\"int-drug\">theophylline</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  theophylline  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">Tiaprofenic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tiaprofenic acid   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tizanidine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">Tolfenamic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tolfenamic acid   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tolterodine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  torasemide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   toremifene .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706937",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706937_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   vandetanib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706938",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706938_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   vardenafil .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706939",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706939_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706940",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706940_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   vemurafenib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706941",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706941_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706942",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706942_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">vilanterol</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  vilanterol  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706943",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706943_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   vinflunine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706944",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706944_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   voriconazole .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706944_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   deflazacort .  Manufacturer advises avoid or monitor side effects .    \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706945",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706945_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the effects of   warfarin .  Manufacturer advises monitor INR .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706946",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706946_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hypokalaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  deflazacort  and  xipamide  can increase the risk of hypokalaemia. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706947",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706947_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">deflazacort</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   deflazacort   (high-dose) .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706948",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2#bnf_i1557280706948_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-heading-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Deflazacort  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/deflazacort-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Deflazacort </title>"
			},
			"rdfs:label": "deflazacort"
		}
	]
}